eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
4/1999
vol. 3
 
Share:
Share:
abstract:

Background of chemoresistance of breast cancer with HER-2/gene amplification and/or overexpression

Ewa Szacikowska
,
Wojciech Kozłowski

Współcz Onkol (1999) 4, 145-151
Online publish date: 2003/08/05
View full text Get citation
 
Results of the most recent basic studies on the cause of chemoresistance of breast cancer epithelial cells with HER-2 gene amplification and/or overexpression are presented. These studies, conducted in cell and animal models, demonstrate that dramatic proliferation of cells accompanying p185 protein (HER-2 gene product) overproduction leads, via the processes of clonal and adaptative selection of resistant tumour cells, to acquired chemoresistance. Therefore, in these cases, this resistance to chemotherapeutics is rather secondary, than connected primarily with HER-2 gene amplification. This can also mean that more aggressive chemotherapy can improve clinical response.

Both the newest and some older clinical papers are presented, which agree with the results of the basic studies as yet, and, analysed together, illustrate adequately the therapeutic problems in breast cancer.

In the paper, most recent methods are also presented of chemotherapy of epithelial tumours with HER-2 gene amplification and/or overexpression, including specific drug administration on molecular target, based on the REC (receptor enhancement chemosensitivity) strategy.
keywords:

breast cancer, chemoresistance, HER-2 gene

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.